- Home
- EAD vs BDTX Comparison
EAD vs BDTX Comparison
Compare EAD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAD
- BDTX
- Stock Information
- Founded
- EAD 2003
- BDTX 2014
- Country
- EAD United States
- BDTX United States
- Employees
- EAD N/A
- BDTX N/A
- Industry
- EAD Finance/Investors Services
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EAD Finance
- BDTX Health Care
- Exchange
- EAD Nasdaq
- BDTX Nasdaq
- Market Cap
- EAD 406.6M
- BDTX 132.5M
- IPO Year
- EAD N/A
- BDTX 2020
- Fundamental
- Price
- EAD $7.13
- BDTX $2.56
- Analyst Decision
- EAD
- BDTX Strong Buy
- Analyst Count
- EAD 0
- BDTX 6
- Target Price
- EAD N/A
- BDTX $14.83
- AVG Volume (30 Days)
- EAD 178.9K
- BDTX 1.2M
- Earning Date
- EAD 01-01-0001
- BDTX 08-05-2025
- Dividend Yield
- EAD 8.91%
- BDTX N/A
- EPS Growth
- EAD N/A
- BDTX N/A
- EPS
- EAD N/A
- BDTX 0.09
- Revenue
- EAD N/A
- BDTX $70,000,000.00
- Revenue This Year
- EAD N/A
- BDTX N/A
- Revenue Next Year
- EAD N/A
- BDTX N/A
- P/E Ratio
- EAD N/A
- BDTX $28.49
- Revenue Growth
- EAD N/A
- BDTX N/A
- 52 Week Low
- EAD $5.69
- BDTX $1.20
- 52 Week High
- EAD $6.81
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- EAD 69.40
- BDTX 59.61
- Support Level
- EAD $7.00
- BDTX $2.43
- Resistance Level
- EAD $7.18
- BDTX $2.72
- Average True Range (ATR)
- EAD 0.05
- BDTX 0.17
- MACD
- EAD 0.01
- BDTX -0.01
- Stochastic Oscillator
- EAD 78.57
- BDTX 75.77
About EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.